Reengineering dendritic cell-based anti-cancer vaccines

Gary K. Koski, Peter A. Cohen, Robert E. Roses, Shuwen Xu, Brian J. Czerniecki

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


Despite initial enthusiasm, dendritic cell (DC)-based anti-cancer vaccines have yet to live up to their promise as one of the best hopes for generating effective anti-tumor immunity. One of the principal reasons for the generally disappointing results achieved thus far could be that the full potential of DCs has not been effectively exploited. Here, we argue that dramatic improvements in vaccine efficacy will probably require a careful re-evaluation of current vaccine design. The formulation of new strategies must take into account the natural history of DCs, particularly their role in helping the immune system deal with infection. Equally critical is the emerging importance of soluble factors, notably interleukin-12, in modulating the quality of immune responses. Vaccines should also be designed to recruit helper T cells and antibody-producing B cells rather than simply cytotoxic T lymphocytes. Finally, the judicious selection of tumor, target antigen, and disease stage best suited for treatment should serve as the foundation of trial designs. Our discussion addresses a recent clinical vaccine trial to treat early breast cancer, where many elements of this new strategy were put into practice.

Original languageEnglish (US)
Pages (from-to)256-276
Number of pages21
JournalImmunological Reviews
Issue number1
StatePublished - Apr 2008


  • Cancer
  • Dendritic cell
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Reengineering dendritic cell-based anti-cancer vaccines'. Together they form a unique fingerprint.

Cite this